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Development of sustained release dosage forms has attracted the attention of phar-
maceutical manufacturers in recent years. Sustained release dosage forms can be formu-
lated into a single unit dosage form such as tablet or capsule, or a multiparticulate do-
sage form such as pellet or bead. Recently, beads have attracted a considerable attention
as potential drug carriers to obtain a controlled release, site-specific delivery and to in-
crease drug bioavailability (1). Alginate and chitosan are the most widely used hydro-
gels in the formulation of such systems due to their high biodegradability and biocom-
patibility. Alginate is a natural polyacid and has a unique property of gel formation in
the presence of multivalent cations such as calcium ions in aqueous media (2), while chi-
tosan is a naturally occurring polysaccharide comprising glucosamine and N-acetyl-glu-
cosamine with unique polycation characteristics (3). Alginate beads have been reported
in some studies for the problems during beads preparation. Drug loss and shrinkage of
31
Acta Pharm. 63 (2013) 31–44 Original research paper
DOI: 10.2478/acph-2013-0003
Development of coated beads for oral controlled delivery
of cefaclor: In vitro evaluation
BAZIGHA K. ABDUL RASOOL1
SAHAR A. FAHMY2
1 Department of Pharmaceutics
and Pharmacy Practice, Dubai Pharmacy
College, Dubai, UAE
2 Department of Pharmaceutics
Faculty of Pharmacy, Helwan University
Helwan, Egypt
Accepted October 2, 2012
The aim of the present study was to develop and charac-
terize coated chitosan-alginate beads containing cefaclor
as a controlled release delivery system. Coated cefaclor
beads were prepared by solvent evaporation techniques.
Beads were found to be intact and spherical in shape.
Their size range was 1.05 to 2.06. The loading efficiency
showed maximum value when the concentration of cefa-
clor, chitosan and PEG 400 was 10 % (m/V), 0.5 % (m/V)
and 2 % (V/V), respectively. Best retardation of cefaclor
release from chitosan-alginate beads was achieved by
coating with 15 % of shellac in formula F19. A significant
antimicrobial activity (p < 0.05) against Staphylococcus au-
reus and Klebsiella pneumoniae was observed for formula
F19 compared to the standard antibiotic disc. Furthermore,
the simulated plasma profile showed the superiority of F19
in sustaining drug release for more than 12 h. Therefore,
shellac coated chitosan-alginate beads could be considered
a successful controlled release oral cefaclor dosage form.
Keywords: cefaclor, chitosan-alginate, shellac coated beads,
modified release, oral delivery
* Correspondence; e-mail: bazigha_rasool@hotmail.com, bazigharasool@yahoo.com
the alginate polymer take place when subjected to an acidic medium, while it dissolves at
higher pH values (2). On the contary, chitosan beads dissolve at low pH and are inso-
luble in alkaline media. Some studies reported that chitosan alone cannot control drug
release due to its hydrophilicity (3). Therefore, the alginate-chitosan polyelectrolyte com-
plex was considered to be a promising medium to reduce the porosity of alginate beads
and decrease the leakage of the encapsulated drug (4). Furthermore, one approach to ob-
taining more controlled release of drugs is the formulation of coated drug beads. Various
coating materials were used for this purpose, such as ethyl cellulose and Eudragit® (5).
In the present study, cefaclor was used as a model drug. Cefaclor is a broad spec-
trum antibiotic belonging to the family of second generation cephalosporins. Cefaclor is
well absorbed in the body, with a peak serum concentration occurring within 30–60 min,
which is significantly reduced in the presence of food, with no change in the total amount
of drug absorbed. Cefaclor is rapidly excreted in urine, with an approximate half-life of
two hours (6). Because of its short half-life and large dose, cefaclor is considered a good
candidate for sustained release dosage forms.
The aim of the present study was to develop a controlled release delivery system of
cefaclor using coated alginate-chitosan beads. The effects of stirring time and the addi-
tion of a solubilizing agent on the encapsulation efficiency, bead size and the drug re-
lease profile were investigated. In addition, the antimicrobial activity of the coated beads of
cefaclor was also evaluated.
EXPERIMENTAL
Materials
Cefaclor was obtained as a gift from Julphar Pharmaceutical Company (UAE). Chi-
tosan (CTS) medium molecular mass, dihydrogen sodium orthophosphate, disodium hy-
drogen orthophosphate and phosphate buffer saline (PBS) tablets (pH 7.4) were all pur-
chased from Sigma-Aldrich (UK). Cellulose acetate phthalate (CAP), calcium chloride,
ethyl cellulose (EC), and shellac (benzyl ethyl 2-methyl-4-(2-phenylethynyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate) were from BDH Chemicals (UK), b-cyclodextrin, sodium
alginate (SA) and oleic acid (OA) sodium were from Hopkin and Williams (UK). All other
chemicals were of analytical grade. Staphylococcus aureus (ATCC 25923) and Klebsiella pneu-
moniae (ATCC 15380) were obtained from the Ibn-Sina Center for drug quality control
and analysis (Iraq).
Preparation of cefaclor loaded beads
Cefaclor loaded beads were prepared using two polymers, alginate and chitosan-
-alginate combination. Table I summarizes the composition of the prepared cefaclor bead
formulations.
Preparation of alginate beads
Alginate beads (F1) were prepared according to the method described by Kikuchi
(7). Two grams of cefaclor were dispersed in 7 % (m/V) sodium alginate aqueous solu-
tion under shaking in a water bath at 40 °C until a homogeneous solution was obtained.
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The pH was adjusted to 5.5 with a few drops of 0.1 mol L–1 NaOH. A volume of 20 mL of
the solution was dropped through a 20 gauge syringe needle into 100 mL of a 3 % (m/V)
calcium chloride aqueous solution. The droplets were slowly stirred for 1 h. Then, algi-
nate beads were separated from the solution, washed several times with distilled water
and dried at 60 °C for 12 h.
Preparation of chitosan-alginate beads
Alginate-chitosan beads (F2-F4) were prepared by the ionotropic gelation method.
Cefaclor was dispersed in a sodium alginate 7 % (m/V) aqueous solution. The solution
was dropped through a 20 gauge syringe needle into 100 mL of a 3 % (m/V) of calcium
chloride agitated solution (pH adjusted to 5.5) containing different concentrations of chi-
tosan (0.2, 0.5 and 0.8 %, m/V) already dissolved in 1 % (V/V) acetic acid solution. Beads
were left for 30 min, and washed twice with distilled water and dried at 50 °C for 4 h,
and then at room temperature for 2 days for complete drying.
Preparation of multilayer chitosan-alginate beads (F5–F10)
Multilayer beads (F5) were prepared by placing the prepared cefaclor-chitosan algi-
nate beads into 100 mL of the post coagulation solution, CTS solution 0.05 % (m/V), for
30 min with stirring. F6 was prepared by placing the beads into 100 mL of 0.05 % CTS
and 100 mL of 0.05 % SA (m/V) for 30 min with stirring. F7 was prepared by incubation
of chitosan-alginate beads in 100 mL of 0.05 % CTS and 100 mL of 0.05 % SA for 30 min,
followed by 10 min stirring in 0.5 % (m/V) CaCl2 aqueous solution. Indeed, F8, F9 and
F10 were prepared using the same former steps but the concentration of coagulation solu-
tions (CTS, SA and CaCl2) was increased to 0.5 % (m/V) (Table I). Chitosan-alginate multi-
layer beads were washed with distilled water and dried in an oven at 30 °C for 24 h.
Preparation of coated beads
Cefaclor loaded chitosan-alginate beads were coated by the solvent evaporation tech-
nique. The beads were coated with ethyl cellulose (EC), cellulose acetate phthalate (CAP)
or shellac. In brief, coating solutions were prepared by placing two grams of dried chito-
san-alginate beads in 20 mL of each of the coating polymer solutions using different concen-
trations: 5, 10 and 15 % (m/V). Formulation compositions (F11-F19) are shown in Table I.
The coating polymeric solutions were prepared as follows. Ethyl cellulose solution was
prepared by dissolving EC in chloroform while CAP and shellac were prepared by dis-
solving the polymer in a 1:1 isopropanol/acetone (V/V) solution. The coating process was
maintained at a stirring rate of 20 rpm and temperature of 50 °C until complete evapo-
ration of the solvent took place. Coated beads were left overnight at room temperature
to ensure solvent evaporation.
In vitro evaluation of the prepared beads
The prepared formulations were evaluated for their morphological features, particle
size, yield percent, entrapment efficiency and in vitro release of cefaclor from the pre-
pared beads.
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Morphological and particle size analysis
An optical microscope (Eclipse TS 100, Nikon, Japan) was used to study the mor-
phology and particle size of dried beads. The microscope eyepiece was fitted with a mi-
crometer by means of which the particle size of the micro-beads could be determined.
The particle size was measured as mean ± SD of 100 examined beads.
Entrapment efficiency
Ten mg of dried loaded beads were pulverized and incubated in 10 mL phosphate
buffer (pH 7.4) at room temperature for 24 h. The suspension was then centrifuged at
6000 rpm for 30 min. The supernatant was assayed for cefaclor using a UV spectrophoto-
meter (Cintra 5, GBC Scientific equipment, Australia) at lmax of 280 nm. The superna-
tant from the empty beads was used as a blank.
In addition, the impact of some factors on the entrapment efficiency of cefaclor in
chitosan-alginate beads (F5) was evaluated including the concentration of chitosan (0,
0.2, 0.5 and 0.8 %, m/V) and cefaclor (5 and 10 % m/V), stirring time (2, 30, 60 and 120 min)
and additives’ types and concentrations: PEG400 1 and 2 % (V/V), oleic acid 1 and 2 % (V/V)
and b-cyclodextrin 1 and 2 % (m/V). Different additives with different concentrations were
added during bead preparation by adding the exact volume of the additive solution to
the dispersion of cefaclor in the chitosan solution with stirring till a homogenous solu-
tion was obtained.
In vitro release study
The in vitro release study of the prepared formulae was carried out using a USP dis-
solution apparatus Type 1 (Copley, UK). The study was carried out by placing a weighed
quantity of beads equivalent to 500 mg cefaclor into hard gelatin capsules, in 900 mL of
different dissolution media ensuring sink conditions. The dissolution media used in the
study were 0.1 mol L–1 HCl (pH 1.2) for 2 h, then acetate buffer (pH 4.6) for 1 h, followed
by phosphate buffer (pH 6.8). The dissolution temperature was maintained at 37 °C with
a rotation rate of 100 rpm. Filtered samples were withdrawn at certain time intervals
and replaced with an equal volume of fresh medium. The samples were analyzed for
cefaclor content using a UV spectrophotometer adjusted to 280 nm (7).
Kinetic analysis of in vitro release
The in vitro drug release profiles of all formulae were analyzed by fitting the first 60 %
fraction of drug released to, the empirical equation proposed by Korsmeyer et al. (9):
Mt / M¥ = k tn
where Mt / M¥ is the fraction of drug released at time t, k is the rate constant and n is the
release exponent. The exponential release constant n was used to characterize the release
mechanism. The rate constant k and the diffusion exponent were calculated from the
intercept and the slope of a logarithmic plot of F vs. t.
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Microbiological study
Antibiotic disc preparation. – Microbiological study of cefaclor released from the se-
lected bead formulation was performed according to the standardized single disc meth-
od as described by Bauer et al. (10). Briefly, the standard antibiotic disc (15 µg per disc)
was prepared by dissolving 1.5 mg of cefaclor in 100 mL of phosphate buffer (pH 7.4).
One milliliter of this solution was placed on a previously prepared multi-filter paper
disc and left to dry for 12 h at room temperature. Sample antibiotic discs were loaded
with one milliliter of cefaclor solution released from F19 in phosphate buffer (pH 7.4)
after 7 and 8 hours of dissolution. This concentration was measured against a previously
prepared cefaclor calibration curve in phosphate buffer pH 7.4 and found to be 15 and
20 µg per disc, respectively.
Antibiotic sensitivity test
Antibiotic sensitivity test was carried out by transferring five colonies of each type
of bacteria, Staphylococcus aureus and Klebsiella pneumoniae from the pure culture to 5 mL
of a nutrient broth tube and incubated at 35 °C for 2–5 h to produce a moderately cloudy
suspension, which was standardized by dilution in turbidity standard barium chloride
solution (TSB), visually equivalent to the McFarland standard 0.5 (standard turbidity pre-
pared by adding 0.5 mL of 1 % barium chloride solution to 99.5 mL of 1 % sulphuric
acid). A volume of 0.1 mL of this suspension was added to non-cultured nutrient agar,
spread using a sterilized swab over the entire agar surface and incubated for 24 h at 37 °C.
The prepared standard and sample antibiotic discs were placed at suitable distances on
the cultured nutrient agar medium and incubated for 24 h at 37 °C and the diameters of
the produced inhibition zones were measured.
In vivo convolution study
Convolution was conducted to simulate the plasma concentration time curves for
cefaclor from F13, F16, F19 and the uncoated bead formulations using spreadsheets. Alt-
hough simulated data are not always close to real data, convolution is still a good tool to
predict the time course of a drug in the body. Convolution was completed with the fol-
lowing assumptions: (i) drug elimination follow first-order elimination, (ii) no absorp-
tion phase is considered; drug is treated like a series of intravenous bolus injections with
appropriate adjustment of bioavailability, (iii) absorption rate constant is greater than the
dissolution rate constant, and (iv) the drug follows linear pharmacokinetics.
Simulated plasma concentration time profiles were compared to those of uncoated
beads and the published data of plasma concentration time profiles for commercially avail-
able cefaclor formulations. The pharmacokinetic parameters (PK) of cefaclor were used
as reported in literature to simulate cefaclor concentration. The following reported PK
were used in the simulation: cefaclor bioavailability from immediate release formulations
reported to be about 80 %, clearance 328.0 ± 83.1 mL min–1 and elimination half-life of
0.6 ± 0.1 h (11).
Statistical analysis
Results are expressed as mean ± SD for triplicate samples. The results were statisti-
cally analyzed to test any significant differences among the groups by the one-way ana-
lysis of variance (ANOVA) using SPSS statistical analysis program version 16.
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RESULTS AND DISCUSSION
Morphological features of the prepared beads
Cefaclor loaded alginate beads (F1 to F4) using calcium chloride with or without
chitosan were evaluated physically and found to be intact and spherical in shape. It was
observed that the addition of chitosan to the coagulation solution produced beads with
a smoother surface then that of alginate alone, as shown in Fig. 1.
Multilayer chitosan-alginate beads (F5–F10) were found to be intact and compact.
Use of chitosan in the preparation of alginate beads resulted in spherical beads with a
smooth surface. This may be attributed to the fact that chitosan bounds electrostatically
to the alginate polymer molecules present on the surface of the beads. The beads that
were additionally treated with sodium alginate (F6 and F9) were found to be clumpy
after washing. An extra treatment with CaCl2 (0.5 %, m/V) also resulted in smooth and
spherical beads (F7 and F10) where Ca2+ ions were cross-linked with the outer most algi-
nate layer of the beads to yield a complex structure (12).
Bead yield and bed size
The yield of prepared beads was almost 80 to 90 % for all the formulations. It was
noticed that the bead yield was slightly lower (70–75 %) in the formulations where chito-
san concentration was low (0.05 %, m/V).
Mean sizes of the prepared beads of different formulations are shown in Table II.
The mean particle size of the prepared beads was in the following order: chitosan-al-
ginate beads (1.05–1.37 mm) < chitosan-alginate multilayer beads (1.34–1.65 mm) <
chitosan-alginate coated beads (1.68–2.08 mm). There was no significant difference in
particle size between multilayer beads (F5, F6 and F7) and chitosan-alginate beads (F3
and F4). However, there was a significant difference (p < 0.05) in particle size between
the multilayer bead formulae (F8, F9 and F10) and the chitosan-alginate bead formulae
(F1, F2, F3 and F4). On the other hand, coated beads were significantly larger than chito-
san-alginate single and multilayer beads.
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Fig. 1. Microscope picture of cefaclor loaded chitosan-alginate beads.
Entrapment efficiency
The effect of certain factors on the entrapment efficiency was studied on a selected
cefaclor formulation (F5) (Table III). Increasing chitosan concentration in the coagulation
solution was found to lead to significant increase in the drug entrapment efficiency with
p < 0.05. Almost the same entrapment efficiency was obtained when chitosan concen-
tration increased from 0.5 to 0.8 % in formulae F3 and F4, respectively. Formula F1, with
no chitosan, showed the lowest drug entrapment efficiency (18.9 %). This may be attri-
buted to gelation of the polymer at pH 4.5 where interaction between the carboxylic
groups of the sodium alginate molecules and the protonated amine groups in chitosan
results in the formation of a firm netlike complex of chitosan-alginate that tightly holds
the drug inside the beads (13). However, the absence of chitosan in formula F1 resulted
in inadequate cross-linking of polymer molecules and led to the formation of large pore
size which permitted drug diffusion and consequently resulted in very low entrapment
efficacy of cefaclor.
Increasing the stirring time during bead preparation resulted in a decrease in cefa-
clor entrapment efficiency, which may be due to the increased possibility of drug leach-
ing outside the beads.
However, increasing the concentration of cefaclor from 5 to 10 % (m/V) resulted in
better drug entrapment in the beads.
The addition of additives during bead preparation resulted in good entrapment effi-
ciency compared to beads with no additive. PEG 400 (2 %) led to a significant increase
(p < 0.05) in the entrapment efficacy compared to beads prepared with the addition of
1 % PEG 400. This may be attributed to the fact that PEG 400 is a solubilizing agent and
freely soluble in water; it therefore enhanced the solubility of cefaclor in sodium alginate
solution and thereby improved the entrapment efficiency of the drug inside the beads.
However, increasing the concentration of oleic acid and b-cyclodextrin from 1 to 2 %
(V/V) did not significantly increase drug entrapment efficiency.
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Table II. Factors affecting cefaclor entrapment efficiency in chitosan-alginate beads
Factor Entrapment efficiency (%)a
Chitosan
(%, m/V)
0 (F1) 0.2 (F2) 0.5 (F3) 0.8 (F4)
18.9 ± 2.5 29.1 ± 4.1 49.0 ± 6.8 49.0 ± 9.6
Stirring time
(min)
2 30 60 120
63.2 ± 7.9 48.9 ± 6.86 34.1 ± 3.9 26.5 ± 5.4
Additive PEG 400 (% V/V) Oleic acid (%, V/V) b-Cyclodextrin (%, m/V)
1 2 1 2 1 2







a Mean ± SD, n = 3.
In vitro drug release
The release profile of cefaclor from bead formulations F1-F4 showed a rapid burst
effect during the first 30 minutes of dissolution (Fig. 2a). This rapid release may be ex-
plained as follows. First, when chitosan-alginate loaded beads were placed at a low pH
(1.2), the negatively charged carboxylate groups of sodium alginate began to protonate
to form uncharged –COOH groups. This reduced the degree of cross linking due to de-
creased electrostatic interactions among the alginate and chitosan chains within the beads,
resulting in increasing fluids uptake and swelling of the beads (12). In addition, cefaclor
as a small, hydrophilic molecules at pH 1.2 is highly ionized, resulting in an increase in
drug solubility; hence it diffuses out easily.
Release profiles of the chitosan-alginate multilayer beads (F5-F10) are shown in Fig.
2b. Increasing chitosan concentration in the multilayered bead formulation F8 resulted
in a decrease in drug release compared to that of formulation F5. In both formulae, de-
protonation of the NH4+ group in the outermost chitosan layer to NH2 groups occurred
upon placing the beads in a simulated intestinal fluid, which can form a diffusion
barrier for Na+/Ca2+ ion exchange among Ca2+ ions in the bulk of the beads and Na+
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n R2 Diffusion model
F1 1.05 ± 0.07 4.321 0.069 0.976 Fickian diffusion
F2 1.18 ± 0.13 4.132 0.125 0.977 Fickian diffusion
F3 1.33 ± 0.09 4.123 0.093 0.984 Fickian diffusion
F4 1.37 ± 0.13 4.057 0.105 0.977 Fickian diffusion
F5 1.34 ± 0.12 4.105 0.0942 0.937 Fickian diffusion
F6 1.36 ± 0.21 4.026 0.111 0.972 Fickian diffusion
F7 1.38 ± 0.27 4.049 0.102 0.976 Fickian diffusion
F8 1.62 ± 0.18 3.916 0.121 0.914 Fickian diffusion
F9 1.65 ± 0.23 3.431 0.208 0.891 Fickian diffusion
F10 1.65 ± 0.15 3.278 0.228 0.901 Fickian diffusion
F11 1.95 ± 0.31 1.459 0.561 0.94 Anomalous diffusion
F12 2.04 ± 0.28 1.442 0.528 0.963 Anomalous diffusion
F13 2.06 ± 0.38 1.144 0.574 0.972 Anomalous diffusion
F14 1.68 ± 0.22 1.87 0.498 0.972 Fickian diffusion
F15 1.81 ± 0.36 1.879 0.497 0.956 Fickian diffusion
F16 1.85 ± 0.27 1.762 0.518 0.972 Anomalous diffusion
F17 1.90 ± 0.34 2.119 0.445 0.973 Fickian diffusion
F18 2.06 ± 0.37 2.134 0.369 0.971 Fickian diffusion
F19 2.08 ± 0.31 2.225 0.365 0.972 Fickian diffusion
a Mean ± SD, n = 3.
ions in the simulated intestinal fluid. By increasing chitosan concentration in the post
coagulation solution (F8), the barrier hindrance also increased and consequently the bead
disintegration process was delayed (14).
It was observed that there was a significant difference in the release profile of F6
and F9 after the first 30 minutes of dissolution. After 30 minutes, F6 released 81 % of
cefaclor compared to 57 % released from formula F9. The outermost layer of both F6
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Fig. 2. Cefaclor release profile from chitosan-
-alginate beads: a) formulated with different
chitosan concentrations; b) multilayered
beads in the post granulation fluid; c) coat-
ed with 5 % (m/V) ethyl cellulose (F11),
CAP (F14) and shellac (F17); d) coated with
10 % (m/V) ethyl cellulose (F12), CAP (F15)
and shellac (F18); e) coated with 15 % (m/V)
ethyl cellulose (F13), CAP (F16) and shellac
(F19).
and F9 was sodium alginate. In simulated gastric fluid (pH 1.2), the negative –COO-
group of sodium alginate got protonated and acted as a diffusion barrier for the release
of the drug. Increasing the thickness of this layer will result in increasing the barrier of
drug diffusion and thereby more retardation in drug release. Upon treating the beads
with simulated intestinal fluids, the alginic acid will begin to dissolve, leaving chitosan
forming the outermost layer. Chitosan will act as a diffusion barrier for Na+/Ca2+ ion
exchange, which will result in delayed drug release. This explain why F9 showed more
delayed drug release than F6 (15).
Drug release from F10 formulations was retarded, with only 65.6 % of the drug re-
lease after 30 minutes of dissolution compared to 80.3 % from formulation F7. This may
be attributed to the addition of calcium chloride where the Ca2+ ions act as a hardening
agent for the outer layer of beads. Therefore, a rigid layer was produced that delayed
diffusion and drug release.
The overall results of release profiles for chitosan-alginate and chitosan-alginate mul-
tilayer beads demonstrate a burst effect during the first hour of dissolution and no pro-
longed release of cefaclor was obtained from the prepared formulations (F5–F10).
Chitosan alginate beads coated with 5 % (m/V) ethyl cellulose (F11), 5 % CAP (F14)
and 5 % (m/V) shellac (F17) showed a delay in drug release from the prepared formula-
tions of 23.7, 33.2 and 30.2 %, respectively, after 30 minutes, compared to 86.6 % of drug
released from the uncoated formulations (Fig. 2c).
Good sustained drug release was obtained from chitosan-alginate coated formula-
tions using 10 % (m/V) of polymeric solutions, especially with 10 % (m/V) of EC (F12)
and shellac (F18) formulations. For F15 bead formulation coated with 10 % (m/V) CAP,
drug release was faster with more than 90 % drug released after 4 h, which was similar
in pattern to the drug released from 5 % (m/V) CAP coated bead formulation. Data are
shown in Fig. 2d.
Increasing the concentration of the coating polymeric solution to 15 % (m/V) (F13,
F16 and F19) showed release patterns dissimilar to those obtained from the 10 % (m/V)
coated formulations. There was a significant difference (p < 0.05) in cefaclor release from
chitosan-alginate beads coated with 15 % (m/V) of polymeric materials compared to 10 %
of the coating polymer (Fig. 2e). F19 (shellac 15 % coated beads) was considered the most
successful formula for controlled cefaclor release and was selected for further study.
Differences in the release profile among coated chitosan-alginate bead formulations
using different polymers are attributed to the differences in solubility of the polymeric
materials used, where CAP solubilizes at pH 5 or more while ethyl cellulose remains
intact throughout the GIT and shellac often dissolves too slowly in the intestinal fluid
(16). As a result, there is faster solubilization of CAP than EC and shellac while the beads
passing through the intestinal fluid (pH 4.6 and 6.8) result in faster drug solubilization
and diffusion into the intestinal fluid.
Kinetic analysis of in vitro drug release
Fractions of the drug released from all developed formulae were fitted using an
empirical equation. Straight lines were obtained from plotting ln Mt/M vs. ln t and
the kinetic parameter (n) was calculated, with the correlation coefficients (R) and 95 %
confidence intervals for all formulations (Table II). The values of n obtained for most
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of the formulations are less than 0.5, which suggests drug release from the prepared for-
mulations via Fickian release mechanism. However, the values of n for the drug released
from CAP coated chitosan-alginate beads were greater than 0.5, indicating anomalous
drug release from the beads by both diffusion and polymer erosion mechanisms.
Microbiological assay
The amount of cefaclor released from F19 after 7 and 8 h was 15 µg and 20 µg, res-
pectively. The growth inhibition zones of both Staphylococcus aureus and Klebsiella pneu-
moniae were measured and significantly higher antibacterial activity (p < 0.05) was ob-
served for formula F19 compared to the standard antibiotic disc (Table IV). These results
demonstrate the efficiency of the new formulation (F19) as a sustained antimicrobial oral
dosage form.
Convolution
Simulation was done to predict the drug plasma concentration from the various for-
mulae administered in vivo. Results are presented in Fig. 3. Simulated data showed that
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Table IV. Inhibition zone diameter (mm) of cefaclor discs incubated in two culture media
Disca Staphylococcus aureusb Klebsiella pneumoniaeb
Cefaclor 24 ± 1 15 ± 0
F19 formula 33 ± 0 17 ± 1
F19 formula 35 ± 1 19 ± 0
a 15 µg per disc
b Mean ± SD, n = 3.
Fig. 3. Simulated Cefaclor plasma concentration time profiles after the administration of 500 mg per
body mass oral dose of selected beads formulations, F13, F16, F19 and the uncoated beads formu-
lations.
uncoated beads produced the highest concentration (gmax) in the blood stream, with a con-
centration of 16.5 mg L–1 reached within 30 minutes, and cefaclor plasma level was low-
er than 0.1 mg L–1 after 8 h. gmax obtained from the uncoated bead formulations was
comparable to that reported for cefaclor immediate release dosage form at a dose of 500 mg
per body mass (17.3 ± 3.6 mg L–1). For formula F13, at the simulated drug plasma profile
was maximum (5.77 mg L–1) after 3 h and cefaclor concentration was less than 0.1 mg L–1
after 12 h, which proves the sustained release action of cefaclor from coated beads for-
mulations. For F16 and F19, the maximum concentration of 9.07 mg L–1 was reached after
2 h and 6.5 mg L–1 after one hour, respectively. Cefaclor concentration reached less than
0.1 mg L–1 after 11 h and 13 h from F16 and F19 formulae, respectively.
The simulated plasma profile for the selected coated formulations showed the su-
periority of F19 and F13 in sustaining drug release for more than 12 h.
CONCLUSIONS
Cefaclor loaded chitosan-alginate coated beads were developed successfully for
modified oral delivery of cefaclor. The desired entrapment efficiency of cefaclor in the
prepared beads was optimized by adjusting different parameters such as polymer type
concentration of the solubilizing agent and stirring time.
The best in vitro sustained release pattern of cefaclor was obtained from bead for-
mulations coated with shellac 15 % (m/V) (F19). In addition, the microbiological activities
demonstrated that F19 is effective against Staphylococcus aureus and Klebsiella pneumoniae.
There was a significant difference in its activity against (p < 0.05) Staphylococcus aureus and
Klebsiella pneumoniae compared to the standard. Convolution of the in vitro dissolution
data showed a good sustained release action from both the F19 and F13 formulae over
12 h.
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